PRODUCT FROM SCN HAS EFFECT ON THE H1N1 VIRUS

(NGM:SCN)

In previous press releases, Scandinavian Clinical Nutrition (SCN) has described positive results from a study where the patented product Immulina has been tested against the influenza virus H1N1, which now has been tied to the swine flu.

The study results showed that taking Immulina caused a significant reduction of both clinical symptoms and lung tissue damage after infection by the influenza virus H1N1, the cause of the new swine flu epidemic, compared to placebo. The study was conducted during 2008 at Louisiana State University in USA, and animal studies have also been conducted at Karolinska Institutet in Stockholm.

Immulina has been developed at the National Center for Natural Products Research at the University of Mississippi. Studies on Immulina and its immune stimulating effects on humans have also been conducted at Rigshospitalet in Copenhagen and the University of Copenhagen, and the results have been published in scientific journals.

For more information, please contact:

Dan Edwall, VP R&D, de@scnutrition.com, +46 707 98 80 89

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition i Sverige AB (publ)) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.com.